Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1(MN) gp120, HIV-1(SF2) recombinant gp120, or both vaccines in seronegative adults

Mary Lou Clements-Mann, Kent Weinhold, Thomas J. Matthews, Barney S. Graham, Geoffrey J. Gorse, Michael C. Keefer, M. Juliana McElrath, Ray Hahn Hsieh, Jiri Mestecky, Susan Zolla-Pazner, John Mascola, David Schwartz, Robert Siliciano, Lawrence Corey, Peter F. Wright, Robert Belshe, Raphael Dolin, Susan Jackson, Serena Xu, Patricia FastMary Clare Walker, Don Stablein, Jean Louis Excler, James Tartaglia, Anne Marie Duliege, Faruk Sinangil, Enzo Paoletti

Research output: Contribution to journalArticlepeer-review

195 Scopus citations

Abstract

A safety and immunogenicity trial was conducted in vaccinia-immune and vaccinia-naive human immunodeficiency virus (HIV)-uninfected adults who were randomized to receive 106 or 107 TCID50 of canarypox (ALVAC) vector expressing HIV-1(MN) gp160 or 105.5 TCID50 of ALVAC-rabies virus glycoprotein control at 0 and 1 or 2 months and ALVAC-gp160 or 50 μg of HIV- 1(SF2) recombinant (r) gp120 in microfluidized emulsion at 9 and 12 months; others received rgp120 at 0, 1, 6, and 12 months. All vaccines were well- tolerated. Neither vaccinia-immune status before vaccination nor ALVAC dose affected HIV immune responses. HIV-1(MN) and HIV-1(SF2) neutralizing antibodies were detected more often (100%) in ALVAC-gp160/rgp120 recipients than in recipients of ALVAC-gp160 (<65%) or rgp120 (89%) alone. ALVAC- gp160/rgp120 also elicited more frequent HIV V3-specific and fusion- inhibition antibodies, antibody-dependent cellular cytotoxicity, lymphoproliferation, and cytotoxic CD8+ T cell activity than did either vaccine alone. Trials with ALVAC expressing additional HIV components and rgp120 are underway.

Original languageEnglish
Pages (from-to)1230-1246
Number of pages17
JournalJournal of Infectious Diseases
Volume177
Issue number5
DOIs
StatePublished - 1998

Fingerprint

Dive into the research topics of 'Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1(MN) gp120, HIV-1(SF2) recombinant gp120, or both vaccines in seronegative adults'. Together they form a unique fingerprint.

Cite this